Hyperinsulinemia and Cognitive Decline in a Middle-Aged Cohort

Author:

Young Sara E.12,Mainous Arch G.1,Carnemolla Mark1

Affiliation:

1. Department of Family Medicine, Medical University of South Carolina, Charleston, South Carolina

2. Department of Family Medicine, Medical College of Georgia, Augusta, Georgia

Abstract

OBJECTIVE—Determining modifiable risks factors for cognitive decline and dementia are a public health priority as we seek to prevent dementia. Type 2 diabetes and related disorders such as hyperinsulinemia increase with aging and are increasing in the U.S. population. Our objective was to determine whether hyperinsulinemia is associated with cognitive decline among middle-aged adults without type 2 diabetes, dementia, or stroke in the Atherosclerosis Risk in Communities (ARIC) cohort. RESEARCH DESIGN AND METHODS—Middle-aged adults (aged 45–64 years at baseline) in the ARIC cohort had fasting insulin and glucose assessed between 1987 and 1989. Subjects with dementia, type 2 diabetes, or stroke at baseline were excluded from analysis. Three tests of cognitive function available at baseline and 6 years later were delayed word recall (DWR), digit symbol subtest (DSS), and first letter word fluency (WF). Cross-sectional comparisons and linear regression models were computed for cognitive tests at baseline and change in cognitive test scores to determine whether cognitive function was associated with two measures of insulin resistance, fasting insulin and homeostasis model assessment (HOMA). Linear regression models controlled for age, sex, race, marital status, education level, smoking status, alcohol use, depression, hypertension, and hyperlipidemia. RESULTS—In unadjusted and adjusted analyses, hyperinsulinemia based on fasting insulin and HOMA at baseline was associated with significantly lower baseline DWR, DSS, and WF scores and a greater decline over 6 years in DWR and WF. CONCLUSIONS—Insulin resistance is a potentially modifiable midlife risk factor for cognitive decline and dementia.

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Reference29 articles.

1. Haan MN, Wallace R: Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 25: 1–24, 2004

2. Xiong G, Doraiswamy PM: Combination drug therapy for Alzheimer’s disease: what is evidence-based, and what is not? Geriatrics 60: 22–26, 2005

3. Schmitt B, Bernhardt T, Moeller H, Heuser I, Frolich L: Combination therapy in Alzheimer’s disease: a review of current evidence. CNS Drugs 18: 827–844, 2004

4. Schulz V: Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trials and guidelines fail to consider. Phytomedicine 10: 74–79, 2003

5. Cowie CC, Rust KF, Byrd-Holt D, Eberhardt MS, Saydah S, Geiss LS, Engelgau MM, Ford ES, Gregg EW: Prevalence of diabetes and impaired fasting glucose in adults: United States, 1999–2000. MMWR 52: 833–837, 2003

Cited by 143 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3